Lannett announced that the FDA has completed its review of the Investigational New Drug Application for biosimilar insulin glargine. Lannett plans to complete the clinical trials by early 2023, with a potential launch in early 2024.
Pearce IP’s Jacinta Flattery-O’Brien Amongst Australia’s Patent Elite – Top 18 Global Leaders Named by IAM
Pearce IP is proud to announce that Jacinta Flattery-O’Brien PhD has again been named as one of Australia’s patent elite in the 2024 edition of IAM...